Related Experiment Video
Updated: Sep 27, 2025
Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
Published on: November 1, 2011
Harnessing Rift Valley fever virus NSs gene for cancer gene therapy
Alicia M Davis1,2, Tristan A Scott3, Kevin V Morris4
1Center for Gene Therapy, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Abstract:
One of the greatest challenges in the treatment of cancer is tumor heterogeneity which results in differential responses to chemotherapy and drugs that work through a single pathway. A therapeutic agent that targets cancer cells for death through multiple mechanisms could be advantageous as a broad inhibitor for many types of cancers and the heterogeneous alterations they possess. Several viral proteins have been exploited for antiproliferative and apoptotic effect in cancer cells by disrupting critical survival pathways. Here, we report the use of the non-structural protein on the S segment (NSs) gene from the Rift Valley fever virus (RVFV) to induce cancer cell death. NSs has immune evasion functions in the context of RVFV with many of these functions affecting proliferation pathways and DNA damage signaling, which could be leveraged against cancer cells. We find that expression of NSs in multiple cancer cell lines leads to a rapid decline in cell viability and induction of apoptosis. Interestingly, we observed reduced toxicity in normal cells suggesting cancer cells may be more susceptible to NSs-mediated cell death. To enhance specificity of NSs for use in hepatocellular carcinoma, we incorporated four miR-122 binding sites in the 3' untranslated region (UTR) of the NSs mRNA to achieve cell type specific expression. Observations presented here collectively suggest that delivery of the NSs gene may provide a unique therapeutic approach in a broad range of cancers.
Insights
The Rift Valley fever virus NSs protein induces cancer cell death and apoptosis. This novel gene therapy approach shows reduced toxicity in normal cells, offering a potential broad-spectrum cancer treatment.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Tumor heterogeneity presents a significant challenge in cancer treatment, leading to varied responses to therapies targeting single pathways.
- Viral proteins offer potential as antiproliferative agents by disrupting cancer cell survival mechanisms.
Purpose of the Study:
- To investigate the potential of the Rift Valley fever virus non-structural protein S (NSs) gene as a therapeutic agent for inducing cancer cell death.
- To evaluate the specificity and efficacy of NSs in targeting cancer cells while minimizing toxicity to normal cells.
Main Methods:
- Expression of the NSs gene from Rift Valley fever virus (RVFV) in various cancer cell lines.
- Assessment of cell viability and induction of apoptosis following NSs gene expression.
- Incorporation of miR-122 binding sites into the NSs mRNA 3' untranslated region (UTR) to enhance specificity for hepatocellular carcinoma.
Main Results:
- NSs gene expression led to a significant decrease in cancer cell viability and induced apoptosis across multiple cancer cell lines.
- Normal cells exhibited reduced toxicity compared to cancer cells, suggesting cancer cell susceptibility to NSs-mediated death.
- Engineered NSs mRNA with miR-122 binding sites demonstrated potential for cell-type-specific expression.
Conclusions:
- The NSs gene holds promise as a therapeutic agent for inducing cancer cell death through multiple mechanisms.
- Targeted delivery of the NSs gene may offer a novel, broad-spectrum therapeutic strategy for various cancers, including hepatocellular carcinoma.
- Further research into NSs gene therapy could lead to innovative treatments for diverse and heterogeneous cancers.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
00:59Gene Therapy
01:29Microorganisms in Medicine and Therapeutics